{"id":"vehicle-sterile-solution","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a sterile, pharmaceutical-grade solution designed to serve as a vehicle for ophthalmic medications or as a control comparator in clinical studies. It contains no active pharmaceutical ingredient and functions primarily as a delivery medium or placebo formulation for eye-related applications.","oneSentence":"Vehicle Sterile Solution is an inert carrier formulation used as a control or diluent in ophthalmic drug delivery systems.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:35:54.683Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Vehicle/control formulation for ophthalmic drug delivery"}]},"trialDetails":[{"nctId":"NCT05608681","phase":"PHASE1, PHASE2","title":"A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).","status":"RECRUITING","sponsor":"Eupraxia Pharmaceuticals Inc.","startDate":"2023-03-31","conditions":"Eosinophilic Esophagitis","enrollment":117},{"nctId":"NCT06538662","phase":"PHASE3","title":"An Investigation of FID 123320 for the Reduction of Ocular Redness in Pediatric and Adult Populations","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2024-10-07","conditions":"Ocular Redness, Eye Irritation","enrollment":283},{"nctId":"NCT03918915","phase":"PHASE3","title":"The Safety and Efficacy of SYD-101 in Children With Myopia","status":"COMPLETED","sponsor":"Sydnexis, Inc.","startDate":"2019-04-24","conditions":"Nearsightedness, Near Sightedness, Near-sightedness","enrollment":852},{"nctId":"NCT05555589","phase":"PHASE3","title":"Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2","status":"RECRUITING","sponsor":"ReGenTree, LLC","startDate":"2023-04-11","conditions":"Neurotrophic Keratopathy","enrollment":70},{"nctId":"NCT05136170","phase":"PHASE3","title":"Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2022-01-27","conditions":"Dry Eye Disease","enrollment":85},{"nctId":"NCT04638660","phase":"PHASE3","title":"Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances","status":"COMPLETED","sponsor":"Ocuphire Pharma, Inc.","startDate":"2020-12-30","conditions":"Dim Light Vision Disturbances","enrollment":144},{"nctId":"NCT05486728","phase":"PHASE2","title":"Phase II Study of SHJ002 Sterile Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease","status":"COMPLETED","sponsor":"Dreamhawk Vision Biotech, Inc.","startDate":"2023-02-08","conditions":"Dry Eye Disease","enrollment":85},{"nctId":"NCT04675151","phase":"PHASE2","title":"Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia","status":"COMPLETED","sponsor":"Ocuphire Pharma, Inc.","startDate":"2021-02-15","conditions":"Presbyopia","enrollment":150},{"nctId":"NCT06520202","phase":"PHASE1, PHASE2","title":"RHPRG4 FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE","status":"TERMINATED","sponsor":"Lubris Bio Pty Ltd","startDate":"2024-11-05","conditions":"Sjogren's Syndrome With Dry Eye","enrollment":8},{"nctId":"NCT06381986","phase":"PHASE2","title":"Efficacy and Safety of SHJ002 Ophthalmic Solution in the Treatment of Corneal Erosion in Sjogren's Patients","status":"COMPLETED","sponsor":"Sunhawk Vision Biotech, Inc.","startDate":"2024-06-28","conditions":"Corneal Erosion","enrollment":116},{"nctId":"NCT06273852","phase":"EARLY_PHASE1","title":"A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors","status":"COMPLETED","sponsor":"Pure Biologics S.A.","startDate":"2024-04-29","conditions":"Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult, Triple Negative Breast Cancer","enrollment":8},{"nctId":"NCT06700070","phase":"EARLY_PHASE1","title":"A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors","status":"RECRUITING","sponsor":"Pure Biologics S.A.","startDate":"2025-03-27","conditions":"Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult, Triple Negative Breast Cancer","enrollment":12},{"nctId":"NCT06774469","phase":"NA","title":"Effect of Overdose Ultrasound on Osteoarthritic Knee in Adult Albino Rat: a Histological Study","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2024-02-07","conditions":"Osteoarthritis of Knee","enrollment":40},{"nctId":"NCT04829344","phase":"PHASE3","title":"A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution","status":"COMPLETED","sponsor":"American Genomics, LLC","startDate":"2021-03-30","conditions":"Anesthesia, Local","enrollment":120},{"nctId":"NCT06533995","phase":"NA","title":"The Usefulness of Visuprime in Cataract Surgery","status":"COMPLETED","sponsor":"VISUfarma SpA","startDate":"2021-10-25","conditions":"Cataract","enrollment":75},{"nctId":"NCT05133180","phase":"PHASE3","title":"Safety and Efficacy Study on Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study)","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2022-01-19","conditions":"Dry Eye","enrollment":104},{"nctId":"NCT06413095","phase":"EARLY_PHASE1","title":"PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS","status":"COMPLETED","sponsor":"Presage Biosciences","startDate":"2022-06-01","conditions":"Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma","enrollment":13},{"nctId":"NCT05877313","phase":"PHASE2","title":"Nitric Oxide Releasing Solution (NORS) For The Treatment Of Human Papillomavirus(HPV) Verrucae Plantaris (Plantar Warts)","status":"COMPLETED","sponsor":"Sanotize Research and Development corp.","startDate":"2023-08-02","conditions":"Verruca Plantaris","enrollment":20},{"nctId":"NCT06348602","phase":"PHASE1, PHASE2","title":"Evaluation of Safety & Efficacy for the Prevention of Ocular GVHD With Ophthalmic Tacrolimus vs Cyclosporine in Allo-HSCT","status":"RECRUITING","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2023-08-01","conditions":"Ocular Graft-versus-host Disease","enrollment":60},{"nctId":"NCT04004507","phase":"PHASE2","title":"Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision Disturbances","status":"COMPLETED","sponsor":"Ocuphire Pharma, Inc.","startDate":"2007-08","conditions":"Decrease in Night Vision, Disturbance; Vision, Loss","enrollment":24},{"nctId":"NCT04778059","phase":"PHASE2","title":"Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19","status":"TERMINATED","sponsor":"US Biotest, Inc.","startDate":"2021-07-27","conditions":"2019 Novel Coronavirus Infection, COVID-19 Virus Infection, SARS Coronavirus 2 Infection","enrollment":21},{"nctId":"NCT04037475","phase":"NA","title":"Treatment of Herpes Labialis by Photodynamic Therapy","status":"COMPLETED","sponsor":"University of Nove de Julho","startDate":"2020-01-01","conditions":"Photodynamic Therapy, Herpes Simplex, Labial","enrollment":24},{"nctId":"NCT06062602","phase":"EARLY_PHASE1","title":"PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC","status":"COMPLETED","sponsor":"Presage Biosciences","startDate":"2021-07-26","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":15},{"nctId":"NCT03960866","phase":"PHASE2","title":"Safety and Efficacy of Ophthalmic Phentolamine Mesylate in Glaucoma","status":"COMPLETED","sponsor":"Ocuphire Pharma, Inc.","startDate":"2019-05-28","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":39},{"nctId":"NCT04620213","phase":"PHASE3","title":"Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis","status":"COMPLETED","sponsor":"Ocuphire Pharma, Inc.","startDate":"2020-11-18","conditions":"Mydriasis, Dilation","enrollment":185},{"nctId":"NCT02600429","phase":"PHASE3","title":"Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1","status":"TERMINATED","sponsor":"ReGenTree, LLC","startDate":"2015-09-17","conditions":"Neurotrophic Keratopathy","enrollment":18},{"nctId":"NCT04024891","phase":"PHASE2","title":"Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis","status":"COMPLETED","sponsor":"Ocuphire Pharma, Inc.","startDate":"2019-08-13","conditions":"Mydriasis, Dilation","enrollment":32},{"nctId":"NCT04620135","phase":"PHASE3","title":"Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2020-11-30","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":245},{"nctId":"NCT05372991","phase":"PHASE1, PHASE2","title":"Safety, Tolerability and Pharmacodynamics Evaluation of CBT-009 Eye Drop","status":"COMPLETED","sponsor":"Cloudbreak Therapeutics, LLC","startDate":"2022-07-20","conditions":"Myopia, Progressive","enrollment":84},{"nctId":"NCT04513652","phase":"PHASE3","title":"A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution","status":"COMPLETED","sponsor":"American Genomics, LLC","startDate":"2020-09-03","conditions":"Anesthesia, Local","enrollment":120},{"nctId":"NCT04065555","phase":"EARLY_PHASE1","title":"Intratumoral Microdosing of TAK-981 in Head and Neck Cancer","status":"COMPLETED","sponsor":"Presage Biosciences","startDate":"2020-10-07","conditions":"Head and Neck Cancer","enrollment":12},{"nctId":"NCT04891718","phase":"EARLY_PHASE1","title":"CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia","status":"WITHDRAWN","sponsor":"Presage Biosciences","startDate":"2021-09-15","conditions":"Solid Tumour","enrollment":""},{"nctId":"NCT03937882","phase":"PHASE3","title":"Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3","status":"COMPLETED","sponsor":"ReGenTree, LLC","startDate":"2019-05-24","conditions":"Dry Eye Syndromes, Dry Eye","enrollment":700},{"nctId":"NCT04272333","phase":"EARLY_PHASE1","title":"Intratumoral Microdosing of Motolimod in HNSCC","status":"TERMINATED","sponsor":"Presage Biosciences","startDate":"2021-10-15","conditions":"HNSCC","enrollment":1},{"nctId":"NCT02974907","phase":"PHASE3","title":"Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2","status":"COMPLETED","sponsor":"ReGenTree, LLC","startDate":"2016-11","conditions":"Dry Eye Syndrome","enrollment":601},{"nctId":"NCT02218489","phase":"PHASE2","title":"Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease","status":"COMPLETED","sponsor":"Kala Pharmaceuticals, Inc.","startDate":"2014-07","conditions":"Blepharitis","enrollment":206},{"nctId":"NCT03691831","phase":"PHASE3","title":"A Study of A-101 Topical Solution for the Treatment of Common Warts","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2018-09-13","conditions":"Common Wart","enrollment":502},{"nctId":"NCT03687372","phase":"PHASE3","title":"Study of A-101 Topical Solution for the Treatment of Common Warts","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2018-09-17","conditions":"Common Wart","enrollment":503},{"nctId":"NCT03770637","phase":"PHASE2","title":"Glucagon Ready to Use (RTU) in Subjects With Hyperinsulinemic Hypoglycemia After Bariatric Surgery","status":"COMPLETED","sponsor":"Xeris Pharmaceuticals","startDate":"2019-05-10","conditions":"Hyperinsulinemic Hypoglycemia","enrollment":14},{"nctId":"NCT03821415","phase":"PHASE2","title":"Effects of RP101 in Post-menopausal Women With Dry Eye Syndrome","status":"COMPLETED","sponsor":"Redwood Pharma AB","startDate":"2019-01-18","conditions":"Dry Eye Syndromes","enrollment":104},{"nctId":"NCT02597803","phase":"PHASE2, PHASE3","title":"Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1","status":"COMPLETED","sponsor":"ReGenTree, LLC","startDate":"2015-09","conditions":"Dry Eye Syndrome","enrollment":317},{"nctId":"NCT01703559","phase":"PHASE2","title":"The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Disturbances","status":"COMPLETED","sponsor":"Ocuphire Pharma, Inc.","startDate":"2011-09-09","conditions":"Night Vision Complaints, Decrease in Night Vision, Disturbance; Vision, Loss","enrollment":60},{"nctId":"NCT00179998","phase":"PHASE2","title":"Effectiveness of Pulmozyme in Infants With Cystic Fibrosis","status":"COMPLETED","sponsor":"Nationwide Children's Hospital","startDate":"2005-01","conditions":"Cystic Fibrosis","enrollment":24},{"nctId":"NCT01023841","phase":"PHASE4","title":"Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-06-01","conditions":"Eyelash Hypotrichosis, Alopecia Areata","enrollment":71},{"nctId":"NCT03615196","phase":"PHASE1","title":"Study of the Safety of USB005 in Healthy Volunteers","status":"COMPLETED","sponsor":"US Biotest, Inc.","startDate":"2018-07-25","conditions":"Healthy Volunteers","enrollment":32},{"nctId":"NCT01977781","phase":"PHASE1","title":"Safety and Efficacy of Topical Tacrolimus 0.05% in the Treatment of Ocular Graft-Versus-Host Disease","status":"COMPLETED","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2013-12","conditions":"Ocular GVHD","enrollment":40},{"nctId":"NCT01984801","phase":"PHASE1","title":"Study to Investigate the Irritation Potential of GSK1940029 Gel","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-10-14","conditions":"Acne Vulgaris","enrollment":54},{"nctId":"NCT01867437","phase":"PHASE1","title":"Effects of RM-493 on Energy Expenditure in Obese Individuals","status":"COMPLETED","sponsor":"Rhythm Pharmaceuticals, Inc.","startDate":"2013-05","conditions":"Obesity, Morbid Obesity","enrollment":15},{"nctId":"NCT02508337","phase":"PHASE3","title":"Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation and Pain","status":"COMPLETED","sponsor":"Xigen SA","startDate":"2015-07","conditions":"Inflammation, Pain, Cataract","enrollment":309},{"nctId":"NCT01393132","phase":"PHASE2","title":"Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye","status":"COMPLETED","sponsor":"Michigan Cornea Consultants, PC","startDate":"2011-03","conditions":"Dry Eye, Sjogren's Syndrome, Graft vs. Host Disease","enrollment":9},{"nctId":"NCT02004626","phase":"PHASE3","title":"Evaluate the Noninferiority of Medicines Treating Uninfected Pressure Ulcers.","status":"WITHDRAWN","sponsor":"Cristália Produtos Químicos Farmacêuticos Ltda.","startDate":"2015-01","conditions":"Pressure Ulcer","enrollment":""},{"nctId":"NCT01387347","phase":"PHASE2","title":"Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry Eye","status":"COMPLETED","sponsor":"ReGenTree, LLC","startDate":"2011-08","conditions":"Dry Eye Syndrome, Dry Eye","enrollment":72},{"nctId":"NCT00753402","phase":"PHASE1","title":"The Effects of Epinephrine in Endotoxemia in Normal Volunteers","status":"COMPLETED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2012-02","conditions":"Immune System","enrollment":37},{"nctId":"NCT01064986","phase":"PHASE1","title":"The Effects of Hydrocortisone in Endotoxemia in Normal Volunteers","status":"COMPLETED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2010-02","conditions":"Infections","enrollment":12},{"nctId":"NCT00693420","phase":"PHASE3","title":"Safety and Efficacy of Bimatoprost Solution in Increasing Overall Eyelash Prominence","status":"COMPLETED","sponsor":"Allergan","startDate":"2007-04","conditions":"Eyelashes","enrollment":278},{"nctId":"NCT00958035","phase":"PHASE4","title":"Study of Bimatoprost Solution in Increasing Eyelash Prominence in African Americans With Eyelash Hypotrichosis","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-11","conditions":"Hypotrichosis","enrollment":89},{"nctId":"NCT00527917","phase":"PHASE2","title":"A Pilot Clinical Investigation of the Efficacy and Safety of Uracyst® Versus Placebo in Patients With Interstitial Cystitis/Painful Bladder Syndrome.","status":"COMPLETED","sponsor":"Watson Pharmaceuticals","startDate":"2007-09","conditions":"Interstitial Cystitis","enrollment":65}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Vehicle Sterile Solution","genericName":"Vehicle Sterile Solution","companyName":"Allergan","companyId":"allergan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vehicle Sterile Solution, also known as MVC-101, is being studied in clinical trials for various conditions including solid tumors and neurotrophic keratopathy. The exact mechanism of action of Vehicle Sterile Solution is unknown.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}